EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Shield-and-Amplify Nanoparticle Vaccines Retune Immunodominance for Broad Protection against SARS-CoV-2

Wenhui Xue, Hong Wang, Sibo Zhang, Hai Li, Lingyan Cui, Miaolin Lan, Yarong Zeng, Hongjing Liu, Lunzhi Yuan, Kun Wu, Ming Zhou, Longmei Zhang und 13 weitere

ACS Nano · 12.11.2026

DOI: 10.1021/acsnano.6c13208 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Nano, online erschienen am 12.11.2026. Verfasst von Wenhui Xue und 24 weiteren Autor:innen. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key Research and Development Program of China, China Postdoctoral Science Foundation, Natural Science Foundation of Fujian Province.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antigenic variation severely constrains the durability and breadth of vaccine-induced protection against rapidly evolving viruses. Although conserved epitopes can support cross-variant immunity, antibody responses to viral glycoproteins are often biased toward exposed, mutable immunodominant epitopes, leaving conserved protective sites subdominant. We previously identified a cryptic, conserved class 5 epitope (the 6D6/7D6 epitope) on the SARS-CoV-2 receptor-binding domain (RBD) capable of eliciting broad cross-neutralization. Here, we present a modular “shield-and-amplify” nanoparticle vaccination strategy to redirect immunodominance toward this subdominant epitope. We engineered site-specific N-linked glycans─alongside the native N343 glycan to mask variable immunodominant regions while preserving accessibility to the class 5 epitope. The resulting glycan-masked RBD antigen (RGM) was displayed on p239 nanoparticles via nanobody-mediated assembly, yielding multivalent RGM@p239 immunogens. Antigenic profiling revealed that glycan shielding preserved recognition by 6D6 and 7D6 antibodies while reducing binding of representative class 1–4 antibodies by at least 80%. In immunized animals, RGM@p239 enriched 7D6-competitive serum antibodies blocking approximately 70–80% of serum binding to RGM and broadened cross-variant neutralization against 8 representative variant strains, including detectable activity against Omicron lineages. Furthermore, RGM@p239 reduced disease severity after Omicron EG.1 challenge in a hamster model. These results support a model in which glycan shielding and nanoparticle multivalency act as complementary immune-focusing modules: shielding attenuates competing responses, while multivalency amplifies responses to conserved subdominant epitopes. This study establishes a nanovaccine design strategy to address antigenic variation by focusing immunity on conserved viral vulnerabilities.

Förderung

  • National Key Research and Development Program of China
  • China Postdoctoral Science Foundation
  • Natural Science Foundation of Fujian Province
  • Fundamental Research Funds for the Central Universities
  • National Natural Science Foundation of China

Zitieren

APA

Xue, W., Wang, H., Zhang, S., Li, H., Cui, L., Lan, M., Zeng, Y., Liu, H., Yuan, L., Wu, K., Zhou, M., Zhang, L., Xiao, J., Chen, Z., Zhang, Y., Li, J., Chen, L., Zhang, Y., Yu, H., …, & Xia, N. (2026). Shield-and-Amplify Nanoparticle Vaccines Retune Immunodominance for Broad Protection against SARS-CoV-2. ACS Nano. https://doi.org/10.1021/acsnano.6c13208

Vancouver

Xue W, Wang H, Zhang S, Li H, Cui L, Lan M, et al. Shield-and-Amplify Nanoparticle Vaccines Retune Immunodominance for Broad Protection against SARS-CoV-2. ACS Nano. 2026. doi:10.1021/acsnano.6c13208

BibTeX
@article{Xue2026,
  author = {Xue, Wenhui and Wang, Hong and Zhang, Sibo and Li, Hai and Cui, Lingyan and Lan, Miaolin and Zeng, Yarong and Liu, Hongjing and Yuan, Lunzhi and Wu, Kun and Zhou, Ming and Zhang, Longmei and Xiao, Jin and Chen, Zihao and Zhang, Yuyun and Li, Jinjin and Chen, Lin and Zhang, Yali and Yu, Hai and Wu, Ting and Ma, Jian and Li, Shaowei and Gu, Ying and Li, Tingting and Xia, Ningshao},
  title = {Shield-and-Amplify Nanoparticle Vaccines Retune Immunodominance for Broad Protection against SARS-CoV-2},
  journal = {ACS Nano},
  year = {2026},
  doi = {10.1021/acsnano.6c13208}
}
Kostenlos starten →